Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN3C2I)

Drug Name

CAR-T cells targeting EphA2 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Malignant glioma	2A00.0	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ephrin type-A receptor 2 (EPHA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BT5528	DMYBKMV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
DS-8895	DM31VNC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
MEDI-547	DM3WP70	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
MEDI-543	DM7Q1PF	Solid tumour/cancer	2A00-2F9Z	Preclinical	[5]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[6]
PMID23489211C20	DMDYC4J	Discovery agent	N.A.	Investigative	[7]
PMID19788238C66	DMCVJK9	Discovery agent	N.A.	Investigative	[8]
PMID21561767C8h	DMABZH6	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT02575261) CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
2	MMAE Delivery Using the Bicycle Toxin Conjugate BT5528. Mol Cancer Ther. 2020 Jul;19(7):1385-1394.
3	Clinical pipeline report, company report or official report of Daiichi Sankyo.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1822).
5	Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15;10(12):1306-14.
6	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
7	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
8	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
9	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.